Next Article in Journal
Novel Aminoguanidine Hydrazone Analogues: From Potential Antimicrobial Agents to Potent Cholinesterase Inhibitors
Next Article in Special Issue
Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
Previous Article in Journal
Teicoplanin—A New Use for an Old Drug in the COVID-19 Era?
Previous Article in Special Issue
Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways
 
 
Article

Article Versions Notes

Pharmaceuticals 2021, 14(12), 1228; https://doi.org/10.3390/ph14121228
Action Date Notes Link
article pdf uploaded. 26 November 2021 11:40 CET Version of Record https://www.mdpi.com/1424-8247/14/12/1228/pdf-vor
article supplementary file uploaded. 26 November 2021 11:40 CET - https://www.mdpi.com/1424-8247/14/12/1228#supplementary
article xml file uploaded 29 November 2021 06:44 CET Original file -
article xml uploaded. 29 November 2021 06:44 CET Update https://www.mdpi.com/1424-8247/14/12/1228/xml
article pdf uploaded. 29 November 2021 06:44 CET Updated version of record https://www.mdpi.com/1424-8247/14/12/1228/pdf
article html file updated 29 November 2021 06:46 CET Original file -
article html file updated 30 July 2022 18:56 CEST Update https://www.mdpi.com/1424-8247/14/12/1228/html
Back to TopTop